首页 > 最新文献

Acta paediatrica (Oslo, Norway : 1992). Supplement最新文献

英文 中文
Growth hormone therapy-established uses in short children. 生长激素疗法已确定用于矮个子儿童。
Pub Date : 2006-07-01 DOI: 10.1080/08035320600649390
W Frederick Schwenk

Unlabelled: Since the first reported efficacious use of human growth hormone in 1958, numerous children have been treated with this hormone. This review discusses the five indications for use of human growth hormone in children that have been approved to date by the United States Food and Drug Administration.

Conclusion: Further, long-term studies will be needed to address the optimal use of this hormone in each of these conditions.

未标注:自1958年首次报道人类生长激素的有效使用以来,许多儿童都接受过这种激素的治疗。本综述讨论了迄今为止美国食品和药物管理局批准的儿童使用人类生长激素的五种适应症。结论:进一步,需要长期的研究来解决这种激素在每种情况下的最佳使用。
{"title":"Growth hormone therapy-established uses in short children.","authors":"W Frederick Schwenk","doi":"10.1080/08035320600649390","DOIUrl":"https://doi.org/10.1080/08035320600649390","url":null,"abstract":"<p><strong>Unlabelled: </strong>Since the first reported efficacious use of human growth hormone in 1958, numerous children have been treated with this hormone. This review discusses the five indications for use of human growth hormone in children that have been approved to date by the United States Food and Drug Administration.</p><p><strong>Conclusion: </strong>Further, long-term studies will be needed to address the optimal use of this hormone in each of these conditions.</p>","PeriodicalId":76973,"journal":{"name":"Acta paediatrica (Oslo, Norway : 1992). Supplement","volume":"95 452","pages":"6-8"},"PeriodicalIF":0.0,"publicationDate":"2006-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08035320600649390","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26111431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Infant leukaemia: clinical, biological and therapeutic advances. 婴儿白血病:临床、生物学和治疗进展。
Pub Date : 2006-07-01 DOI: 10.1111/j.1651-2227.2006.tb02416.x
Matteo Luciani, Ippolita Rana, Valecia Pansini, Mauzilio Caniglia, Valentina Coletti, Alice Maraschini, Alessandra Lombardi, Giulio De Rossi

Unlabelled: Infant acute lymphoid leukaemia (IALL) represents a distinct subset with an extremely poor response to therapy, despite major progress in the treatment of childhood leukaemia. However, several studies have shown that, even in this generally considered homogeneous group, a distinction could be made with regard to prognosis. The outcome of IALL patients with ALL-1/MLL rearrangements at the 11q23 cytogenetic band, early pre-B immunophenotype, high WBC count and age below 6 mo is significantly worse than in patients without these characteristics, and current therapies appear inadequate in a significant number of cases. Therefore, an international protocol (Interfant 99) was recently started, using a more aggressive approach, which included lymphoid- and myeloid-specific drugs, and indications for stem-cell transplantation. We reviewed the clinical characteristics of the disease, the results of several recent international clinical trials, and our experience with 16 infants with acute lymphoid leukaemia diagnosed and treated at our institution.

Conclusion: It is extremely important to stratify patients for prognosis, taking into account clinical and biological variables with independent prognostic value. The aim is to select more adequate, risk-adapted, therapeutic strategies which also consider related or unrelated bone marrow transplant consolidation for patients with very poor prognosis.

未标记:尽管儿童白血病的治疗取得了重大进展,但婴儿急性淋巴细胞白血病(IALL)是一个对治疗反应极差的独特亚群。然而,一些研究表明,即使在这个通常被认为是同质的群体中,也可以在预后方面做出区分。11q23细胞遗传带ALL-1/MLL重排、早期b前免疫表型、高WBC计数和年龄小于6个月的IALL患者的预后明显差于没有这些特征的患者,并且目前的治疗方法在相当数量的病例中显得不足。因此,最近开始了一项国际协议(interant 99),采用了一种更积极的方法,包括淋巴细胞和骨髓特异性药物,以及干细胞移植的适应症。我们回顾了该疾病的临床特征,最近几项国际临床试验的结果,以及我们在我院诊断和治疗的16例急性淋巴性白血病婴儿的经验。结论:考虑具有独立预后价值的临床和生物学变量,对患者进行预后分层极为重要。目的是为预后非常差的患者选择更充分、更适合风险的治疗策略,同时考虑相关或不相关的骨髓移植巩固。
{"title":"Infant leukaemia: clinical, biological and therapeutic advances.","authors":"Matteo Luciani, Ippolita Rana, Valecia Pansini, Mauzilio Caniglia, Valentina Coletti, Alice Maraschini, Alessandra Lombardi, Giulio De Rossi","doi":"10.1111/j.1651-2227.2006.tb02416.x","DOIUrl":"10.1111/j.1651-2227.2006.tb02416.x","url":null,"abstract":"<p><strong>Unlabelled: </strong>Infant acute lymphoid leukaemia (IALL) represents a distinct subset with an extremely poor response to therapy, despite major progress in the treatment of childhood leukaemia. However, several studies have shown that, even in this generally considered homogeneous group, a distinction could be made with regard to prognosis. The outcome of IALL patients with ALL-1/MLL rearrangements at the 11q23 cytogenetic band, early pre-B immunophenotype, high WBC count and age below 6 mo is significantly worse than in patients without these characteristics, and current therapies appear inadequate in a significant number of cases. Therefore, an international protocol (Interfant 99) was recently started, using a more aggressive approach, which included lymphoid- and myeloid-specific drugs, and indications for stem-cell transplantation. We reviewed the clinical characteristics of the disease, the results of several recent international clinical trials, and our experience with 16 infants with acute lymphoid leukaemia diagnosed and treated at our institution.</p><p><strong>Conclusion: </strong>It is extremely important to stratify patients for prognosis, taking into account clinical and biological variables with independent prognostic value. The aim is to select more adequate, risk-adapted, therapeutic strategies which also consider related or unrelated bone marrow transplant consolidation for patients with very poor prognosis.</p>","PeriodicalId":76973,"journal":{"name":"Acta paediatrica (Oslo, Norway : 1992). Supplement","volume":"95 452","pages":"47-51"},"PeriodicalIF":0.0,"publicationDate":"2006-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26110167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surgery in disabled children: general gastroenterological aspects. 残疾儿童的外科手术:一般胃肠病学方面。
Pub Date : 2006-07-01 DOI: 10.1080/08035320600649697
Emanuela Ceriati, Francesco De Peppo, Guido Ciprandi, Paola Marchetti, Massimiliano Silveri, Massimo Rivosecchi

Unlabelled: Cerebral palsy (CP) is a non-progressive but not unchanging disorder of movement and/or posture, due to an insult to or anomaly of the developing brain. Gastrointestinal surgery can play a role in the treatment of pathologies frequently associated with a condition of neurological impairment such as gastro-oesophageal reflux disease (antireflux procedure), feeding difficulties (percutaneous endoscopic gastrostomy/jejunostomy) and swallowing difficulties (ligation of salivary gland ducts). Gastro-oesophageal reflux occurs in up to 70-75% of children with cerebral palsy. Children with gastro-oesophageal reflux disease (GERD) may present with feeding difficulties, recurrent vomiting and recurrent chest infection associated with poor growth and nutrition, reactive airway disease particularly nocturnal asthma, choking attacks, anaemia, and wheezing. Nutritional deprivation in children with cerebral palsy is the summation of several factors which result in reduced intake. Percutaneous endoscopic gastrostomy (PEG) has radically changed the handling of children with nutritional problems who, before the introduction of this procedure, were force fed parenterally or enterally, by nasogastric tube, conventional surgical gastrostomy or central venous access. In children with CP, PEG is the preferred technique for long-term enteral feeding. Swallowing dysfunction is the main cause of drooling in cerebral palsy, and medical treatment is often inefficient. Surgical treatment involves neurectomy, translocation of the salivary duct, salivary gland resection or salivary duct (parotid and submandibular) ligation.

Conclusion: This review focuses on the role of surgery in managing gastrointestinal aspects in children with CP and, in particular, surgical experience at our department with fundoplication, PEG placement and ligation of salivary ducts.

未标示:脑瘫(CP)是一种非进行性但并非一成不变的运动和/或姿势障碍,由发育中的大脑受到损伤或异常引起。胃肠外科手术可在治疗常与神经损伤相关的病理方面发挥作用,如胃食管反流病(抗反流手术)、进食困难(经皮内镜胃造口术/空肠造口术)和吞咽困难(唾腺导管结扎)。高达70-75%的脑瘫儿童发生胃食管反流。患有胃食管反流病(GERD)的儿童可能出现喂养困难、反复呕吐和与生长不良和营养不良相关的反复胸部感染、反应性气道疾病(尤其是夜间哮喘)、窒息发作、贫血和喘息。脑瘫儿童的营养剥夺是导致摄入量减少的几个因素的总和。经皮内窥镜胃造口术(PEG)从根本上改变了对有营养问题的儿童的处理,在引入该手术之前,儿童通过鼻胃管、传统外科胃造口术或中心静脉通道进行肠外或肠内强制喂养。在患有CP的儿童中,PEG是长期肠内喂养的首选技术。吞咽功能障碍是脑瘫患者流口水的主要原因,而药物治疗往往无效。手术治疗包括神经切除术、唾液管移位、唾液腺切除术或唾液管(腮腺和下颌下)结扎。结论:本文综述了手术在治疗CP患儿胃肠道方面的作用,特别是我科在基础折叠、PEG放置和唾液管结扎方面的手术经验。
{"title":"Surgery in disabled children: general gastroenterological aspects.","authors":"Emanuela Ceriati,&nbsp;Francesco De Peppo,&nbsp;Guido Ciprandi,&nbsp;Paola Marchetti,&nbsp;Massimiliano Silveri,&nbsp;Massimo Rivosecchi","doi":"10.1080/08035320600649697","DOIUrl":"https://doi.org/10.1080/08035320600649697","url":null,"abstract":"<p><strong>Unlabelled: </strong>Cerebral palsy (CP) is a non-progressive but not unchanging disorder of movement and/or posture, due to an insult to or anomaly of the developing brain. Gastrointestinal surgery can play a role in the treatment of pathologies frequently associated with a condition of neurological impairment such as gastro-oesophageal reflux disease (antireflux procedure), feeding difficulties (percutaneous endoscopic gastrostomy/jejunostomy) and swallowing difficulties (ligation of salivary gland ducts). Gastro-oesophageal reflux occurs in up to 70-75% of children with cerebral palsy. Children with gastro-oesophageal reflux disease (GERD) may present with feeding difficulties, recurrent vomiting and recurrent chest infection associated with poor growth and nutrition, reactive airway disease particularly nocturnal asthma, choking attacks, anaemia, and wheezing. Nutritional deprivation in children with cerebral palsy is the summation of several factors which result in reduced intake. Percutaneous endoscopic gastrostomy (PEG) has radically changed the handling of children with nutritional problems who, before the introduction of this procedure, were force fed parenterally or enterally, by nasogastric tube, conventional surgical gastrostomy or central venous access. In children with CP, PEG is the preferred technique for long-term enteral feeding. Swallowing dysfunction is the main cause of drooling in cerebral palsy, and medical treatment is often inefficient. Surgical treatment involves neurectomy, translocation of the salivary duct, salivary gland resection or salivary duct (parotid and submandibular) ligation.</p><p><strong>Conclusion: </strong>This review focuses on the role of surgery in managing gastrointestinal aspects in children with CP and, in particular, surgical experience at our department with fundoplication, PEG placement and ligation of salivary ducts.</p>","PeriodicalId":76973,"journal":{"name":"Acta paediatrica (Oslo, Norway : 1992). Supplement","volume":"95 452","pages":"34-7"},"PeriodicalIF":0.0,"publicationDate":"2006-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08035320600649697","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26111930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 24
Non-conventional use of growth hormone therapy. 非常规使用生长激素疗法。
Pub Date : 2006-07-01 DOI: 10.1080/08035320600649432
Marco Cappa, Graziamaria Ubertini, Diego Colabianchi, Rossana Fiori, Paola Cambiaso

Unlabelled: Human growth hormone therapy is allowed in certain clinical conditions according to national healthcare criteria. Growth hormone, however, produces a wide spectrum of effects. Linear growth is only one of the many expected results, and there are interesting possibilities to explore which could provide additional means of improving the quality of life for the ever-increasing numbers of chronic paediatric patients.

Conclusion: In this review, we discuss the rationale for and possibility of using growth hormone therapy in some conditions not strictly related to growth hormone deficiency.

未标明:根据国家卫生保健标准,在某些临床条件下允许使用人类生长激素治疗。然而,生长激素会产生广泛的影响。线性增长只是众多预期结果之一,还有一些有趣的可能性可以探索,这些可能性可以为不断增加的慢性儿科患者提供额外的改善生活质量的方法。结论:本文讨论了生长激素治疗与生长激素缺乏无关的一些疾病的基本原理和可能性。
{"title":"Non-conventional use of growth hormone therapy.","authors":"Marco Cappa,&nbsp;Graziamaria Ubertini,&nbsp;Diego Colabianchi,&nbsp;Rossana Fiori,&nbsp;Paola Cambiaso","doi":"10.1080/08035320600649432","DOIUrl":"https://doi.org/10.1080/08035320600649432","url":null,"abstract":"<p><strong>Unlabelled: </strong>Human growth hormone therapy is allowed in certain clinical conditions according to national healthcare criteria. Growth hormone, however, produces a wide spectrum of effects. Linear growth is only one of the many expected results, and there are interesting possibilities to explore which could provide additional means of improving the quality of life for the ever-increasing numbers of chronic paediatric patients.</p><p><strong>Conclusion: </strong>In this review, we discuss the rationale for and possibility of using growth hormone therapy in some conditions not strictly related to growth hormone deficiency.</p>","PeriodicalId":76973,"journal":{"name":"Acta paediatrica (Oslo, Norway : 1992). Supplement","volume":"95 452","pages":"9-13"},"PeriodicalIF":0.0,"publicationDate":"2006-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08035320600649432","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26111924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Dilated cardiomyopathy in children. 儿童扩张型心肌病。
Pub Date : 2006-07-01 DOI: 10.1080/08035320600649358
Maria Giulia Gagliardi

Unlabelled: Dilated cardiomyopathy (DCM) is a rare disease in the paediatric population. We analysed the epidemiology, clinical features and role of immunotherapy in the treatment of myocarditis. On the basis of experimental evidence, indicating that autoimmunity might play a role in the development of myocarditis, we treated children affected by myocarditis with immunosuppressive therapy, and we present here our series. The future availability of reliable prognostic markers should allow treatment of only those children with myocarditis who do not spontaneously recover. The possibility that DCM with myocarditis is a distinct pathological entity from the non-inflammatory form of DCM is suggested.

Conclusion: The high long-term survival rate observed in our children with myocarditis is probably due to the effect of short-term immunosuppression. This result is at odds with previously published series of conventionally treated children, whose survival probability at 1 y was approximately 0.60.

未标记:扩张型心肌病(DCM)是一种罕见的疾病在儿科人群。我们分析了心肌炎的流行病学、临床特点及免疫治疗在心肌炎中的作用。在实验证据的基础上,表明自身免疫可能在心肌炎的发展中起作用,我们用免疫抑制疗法治疗心肌炎患儿,并在此提出我们的系列。未来可靠的预后标记物的可用性应该允许仅治疗那些患有心肌炎但不能自行恢复的儿童。伴有心肌炎的DCM可能是一种不同于非炎症形式的DCM的病理实体。结论:小儿心肌炎长期生存率高,可能与短期免疫抑制作用有关。这一结果与先前发表的一系列常规治疗儿童的结果不一致,这些儿童在1岁时的存活率约为0.60。
{"title":"Dilated cardiomyopathy in children.","authors":"Maria Giulia Gagliardi","doi":"10.1080/08035320600649358","DOIUrl":"https://doi.org/10.1080/08035320600649358","url":null,"abstract":"<p><strong>Unlabelled: </strong>Dilated cardiomyopathy (DCM) is a rare disease in the paediatric population. We analysed the epidemiology, clinical features and role of immunotherapy in the treatment of myocarditis. On the basis of experimental evidence, indicating that autoimmunity might play a role in the development of myocarditis, we treated children affected by myocarditis with immunosuppressive therapy, and we present here our series. The future availability of reliable prognostic markers should allow treatment of only those children with myocarditis who do not spontaneously recover. The possibility that DCM with myocarditis is a distinct pathological entity from the non-inflammatory form of DCM is suggested.</p><p><strong>Conclusion: </strong>The high long-term survival rate observed in our children with myocarditis is probably due to the effect of short-term immunosuppression. This result is at odds with previously published series of conventionally treated children, whose survival probability at 1 y was approximately 0.60.</p>","PeriodicalId":76973,"journal":{"name":"Acta paediatrica (Oslo, Norway : 1992). Supplement","volume":"95 452","pages":"14-6"},"PeriodicalIF":0.0,"publicationDate":"2006-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08035320600649358","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26111925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unifocalization and repair of pulmonary atresia with ventricular septal defect and major aortopulmonary collateral arteries. 合并室间隔缺损及主主动脉-肺侧支肺动脉闭锁的定位与修复。
Pub Date : 2006-07-01 DOI: 10.1080/08035320600649333
Adriano Carotti, Sonia B Albanese, Roberto M Di Donato
AIMTo correlate anatomic and genetic features of paediatric patients with pulmonary atresia, ventricular septal defect (VSD) and multiple aortopulmonary collateral arteries with surgical outcome.METHODS44 consecutive patients aged 33 +/- 40 mo underwent either primary one-stage unifocalization (n = 32) or palliative right ventricular outflow tract reconstruction (n = 12) followed by secondary unifocalization and repair (n = 10) based on preoperative morphometric and functional evaluation of pulmonary blood sources. Chromosome 22q11.2 microdeletion occurred in 41% of cases. Combined VSD closure during one-stage procedures was guided by an intraoperative pulmonary flow study. Complete repair was accomplished in 35 cases (83%, 95% CI 72-95%). Variables examined included occurrence of confluent intrapericardial pulmonary arteries, central pulmonary arteries, confluent intraparenchymal pulmonary arteries, dominant collateral or pulmonary arteries, and chromosome 22q11.2 microdeletion. The sensitivity and specificity of the pulmonary flow study in predicting postoperative pulmonary haemodynamics were also tested.RESULTSEight-year actuarial survival and freedom from reoperation were 85% and 63%, respectively. Sensitivity and specificity of the pulmonary flow study were 94% and 100%, respectively. None of the anatomical variables examined was significantly related to the outcome of treatment. The only statistically relevant association was detected between survival and occurrence of 22q11.2 microdeletion (p < 0.003). Logistic analysis showed an increased likelihood of positive outcome in relation to first- (p < 0.02) or second-stage (p < 0.04) complete correction.CONCLUSIONMorphology of pulmonary blood supply has no major impact on surgical outcome. Pulmonary flow study is a highly specific and sensitive intraoperative test. Chromosome 22q11.2 microdeletion remains the only variable significantly affecting survival.
目的:探讨小儿肺闭锁、室间隔缺损(VSD)和肺动脉多支侧支的解剖学和遗传学特征与手术预后的关系。方法:44例年龄33 +/- 40个月的连续患者,根据术前肺血源形态测量和功能评估,分别进行了一期单点定位(n = 32)或姑息性右心室流出道重建(n = 12),随后进行了二期单点定位和修复(n = 10)。22q11.2染色体微缺失发生率为41%。术中肺血流研究指导一期手术期间联合室间隔关闭。35例完全修复(83%,95% CI 72-95%)。检查的变量包括心包内肺动脉、中央肺动脉、肺实质内肺动脉、显性侧支或肺动脉的发生情况,以及染色体22q11.2微缺失。肺血流研究在预测术后肺血流动力学方面的敏感性和特异性也进行了测试。结果:8年精算生存率为85%,再手术自由度为63%。肺血流研究的敏感性和特异性分别为94%和100%。所有解剖变量均与治疗结果无显著相关性。生存率与22q11.2微缺失的发生率之间存在统计学相关性(p < 0.003)。逻辑分析显示,与第一阶段(p < 0.02)或第二阶段(p < 0.04)完全校正相关,阳性结果的可能性增加。结论:肺血供形态对手术结果无重大影响。肺血流研究是一种高度特异性和敏感性的术中检测方法。染色体22q11.2微缺失仍然是唯一显著影响存活的变量。
{"title":"Unifocalization and repair of pulmonary atresia with ventricular septal defect and major aortopulmonary collateral arteries.","authors":"Adriano Carotti,&nbsp;Sonia B Albanese,&nbsp;Roberto M Di Donato","doi":"10.1080/08035320600649333","DOIUrl":"https://doi.org/10.1080/08035320600649333","url":null,"abstract":"AIM\u0000To correlate anatomic and genetic features of paediatric patients with pulmonary atresia, ventricular septal defect (VSD) and multiple aortopulmonary collateral arteries with surgical outcome.\u0000\u0000\u0000METHODS\u000044 consecutive patients aged 33 +/- 40 mo underwent either primary one-stage unifocalization (n = 32) or palliative right ventricular outflow tract reconstruction (n = 12) followed by secondary unifocalization and repair (n = 10) based on preoperative morphometric and functional evaluation of pulmonary blood sources. Chromosome 22q11.2 microdeletion occurred in 41% of cases. Combined VSD closure during one-stage procedures was guided by an intraoperative pulmonary flow study. Complete repair was accomplished in 35 cases (83%, 95% CI 72-95%). Variables examined included occurrence of confluent intrapericardial pulmonary arteries, central pulmonary arteries, confluent intraparenchymal pulmonary arteries, dominant collateral or pulmonary arteries, and chromosome 22q11.2 microdeletion. The sensitivity and specificity of the pulmonary flow study in predicting postoperative pulmonary haemodynamics were also tested.\u0000\u0000\u0000RESULTS\u0000Eight-year actuarial survival and freedom from reoperation were 85% and 63%, respectively. Sensitivity and specificity of the pulmonary flow study were 94% and 100%, respectively. None of the anatomical variables examined was significantly related to the outcome of treatment. The only statistically relevant association was detected between survival and occurrence of 22q11.2 microdeletion (p < 0.003). Logistic analysis showed an increased likelihood of positive outcome in relation to first- (p < 0.02) or second-stage (p < 0.04) complete correction.\u0000\u0000\u0000CONCLUSION\u0000Morphology of pulmonary blood supply has no major impact on surgical outcome. Pulmonary flow study is a highly specific and sensitive intraoperative test. Chromosome 22q11.2 microdeletion remains the only variable significantly affecting survival.","PeriodicalId":76973,"journal":{"name":"Acta paediatrica (Oslo, Norway : 1992). Supplement","volume":"95 452","pages":"22-6"},"PeriodicalIF":0.0,"publicationDate":"2006-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08035320600649333","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26111927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Ethical issues in neonatal intensive care and physicians' practices: a European perspective. 新生儿重症监护和医生实践中的伦理问题:欧洲视角。
Pub Date : 2006-07-01 DOI: 10.1111/j.1651-2227.2006.tb02415.x
Marina Cuttini, Veronica Casotto, Marcello Orzalesi

Unlabelled: An international project (EURONIC) was carried out to explore the end-of-life decision-making process in a large, representative sample of neonatal intensive care units (NICUs) in eight western European countries: France, Germany, Great Britain, Italy, Luxembourg, the Netherlands, Spain and Sweden. Structured questionnaires were used to record data on NICU organization and policies, and to survey staff views and practices regarding ethical decision-making. One hundred and twenty-two NICUs were recruited by census or random sampling (response rate 86%); 1235 physicians and 3115 nurses completed the staff questionnaire (response rates 89 and 85%, respectively). This paper focuses on the physicians' answers. In all countries but Italy, most physicians reported having been involved at least once in setting limits to intensive care because of a baby's incurable condition and/or poor neurological prognosis. Adopted strategies varied between countries. Practices such as the continuation of current treatment without intensifying it and the withholding of emergency manoeuvres appeared widespread. In contrast, the frequency of doctors reporting withdrawal of mechanical ventilation was highest in the Netherlands (93%), Sweden (91%) and the Great Britain (88%), intermediate in France and Germany, and lowest in Spain and Italy (34 and 21%, respectively).

Conclusion: Ethically problematic clinical cases are approached differently in the various countries. The findings of this study may provide an opportunity for physicians to review their practices critically, in light of how other colleagues proceed, and foster an open discussion about these difficult issues.

未标记:一项国际项目(EURONIC)在八个西欧国家(法国、德国、英国、意大利、卢森堡、荷兰、西班牙和瑞典)的新生儿重症监护病房(nicu)中开展,以探索生命末期决策过程。使用结构化问卷记录新生儿重症监护室组织和政策的数据,并调查工作人员对道德决策的看法和做法。采用普查或随机抽样方法纳入新生儿重症监护病房122例(有效率86%);1235名医生和3115名护士完成了员工问卷(回复率分别为89%和85%)。本文主要关注医生的回答。在除意大利以外的所有国家,大多数医生报告说,由于婴儿的无法治愈的状况和/或不良的神经预后,他们至少参与过一次对重症监护的限制。各国采取的战略各不相同。诸如继续目前的治疗而不加强治疗和停止紧急演习等做法似乎很普遍。相比之下,医生报告停止机械通气的频率在荷兰(93%)、瑞典(91%)和英国(88%)最高,法国和德国居中,西班牙和意大利最低(分别为34%和21%)。结论:不同国家对伦理问题临床病例的处理方式不同。这项研究的发现可能为医生提供了一个机会,根据其他同事的做法,批判性地回顾他们的实践,并促进对这些困难问题的公开讨论。
{"title":"Ethical issues in neonatal intensive care and physicians' practices: a European perspective.","authors":"Marina Cuttini, Veronica Casotto, Marcello Orzalesi","doi":"10.1111/j.1651-2227.2006.tb02415.x","DOIUrl":"10.1111/j.1651-2227.2006.tb02415.x","url":null,"abstract":"<p><strong>Unlabelled: </strong>An international project (EURONIC) was carried out to explore the end-of-life decision-making process in a large, representative sample of neonatal intensive care units (NICUs) in eight western European countries: France, Germany, Great Britain, Italy, Luxembourg, the Netherlands, Spain and Sweden. Structured questionnaires were used to record data on NICU organization and policies, and to survey staff views and practices regarding ethical decision-making. One hundred and twenty-two NICUs were recruited by census or random sampling (response rate 86%); 1235 physicians and 3115 nurses completed the staff questionnaire (response rates 89 and 85%, respectively). This paper focuses on the physicians' answers. In all countries but Italy, most physicians reported having been involved at least once in setting limits to intensive care because of a baby's incurable condition and/or poor neurological prognosis. Adopted strategies varied between countries. Practices such as the continuation of current treatment without intensifying it and the withholding of emergency manoeuvres appeared widespread. In contrast, the frequency of doctors reporting withdrawal of mechanical ventilation was highest in the Netherlands (93%), Sweden (91%) and the Great Britain (88%), intermediate in France and Germany, and lowest in Spain and Italy (34 and 21%, respectively).</p><p><strong>Conclusion: </strong>Ethically problematic clinical cases are approached differently in the various countries. The findings of this study may provide an opportunity for physicians to review their practices critically, in light of how other colleagues proceed, and foster an open discussion about these difficult issues.</p>","PeriodicalId":76973,"journal":{"name":"Acta paediatrica (Oslo, Norway : 1992). Supplement","volume":"95 452","pages":"42-6"},"PeriodicalIF":0.0,"publicationDate":"2006-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26110166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What makes the heart fail? New insights from defective genes. 是什么导致心脏衰竭?来自缺陷基因的新见解。
Pub Date : 2006-07-01 DOI: 10.1080/08035320600649325
Timothy M Olson

Unlabelled: Dilated cardiomyopathy (DCM) is an idiopathic, genetically heterogeneous disorder characterized by heart failure and arrhythmia. Over the past decade, the molecular basis for DCM has been partially uncovered by discovery of mutation in genes encoding cystoskeletal, sarcomeric, nuclear membrane, and sarcoplasmic reticulum proteins. These findings have implicated pathogenic mechanisms whereby structural integrity, contractile force dynamics, and calcium regulation within the cardiac myocyte are perturbed. Recognition of dilated and hypertrophic cardiomyopathies as allelic disorders has provided the opportunity to identify genotype-phenotype relationships and to gain new insight into pathways leading to cardiac failure and hypertrophy.

Conclusion: Collectively, family-based studies of DCM provide the rationale for clinical screening in first-degree relatives, regardless of family history or age of the index case.

扩张型心肌病(DCM)是一种特发性、遗传异质性疾病,以心力衰竭和心律失常为特征。在过去的十年中,DCM的分子基础已经部分揭示了基因突变的发现,编码囊骨蛋白,肉瘤蛋白,核膜蛋白和肌浆网蛋白。这些发现暗示了结构完整性、收缩力动力学和心肌细胞内钙调节受到干扰的致病机制。认识到扩张型和肥厚型心肌病是等位基因疾病,为确定基因型-表型关系提供了机会,并获得了导致心力衰竭和肥厚途径的新见解。结论:总的来说,基于家庭的DCM研究为一级亲属的临床筛查提供了依据,无论其家族史或年龄如何。
{"title":"What makes the heart fail? New insights from defective genes.","authors":"Timothy M Olson","doi":"10.1080/08035320600649325","DOIUrl":"https://doi.org/10.1080/08035320600649325","url":null,"abstract":"<p><strong>Unlabelled: </strong>Dilated cardiomyopathy (DCM) is an idiopathic, genetically heterogeneous disorder characterized by heart failure and arrhythmia. Over the past decade, the molecular basis for DCM has been partially uncovered by discovery of mutation in genes encoding cystoskeletal, sarcomeric, nuclear membrane, and sarcoplasmic reticulum proteins. These findings have implicated pathogenic mechanisms whereby structural integrity, contractile force dynamics, and calcium regulation within the cardiac myocyte are perturbed. Recognition of dilated and hypertrophic cardiomyopathies as allelic disorders has provided the opportunity to identify genotype-phenotype relationships and to gain new insight into pathways leading to cardiac failure and hypertrophy.</p><p><strong>Conclusion: </strong>Collectively, family-based studies of DCM provide the rationale for clinical screening in first-degree relatives, regardless of family history or age of the index case.</p>","PeriodicalId":76973,"journal":{"name":"Acta paediatrica (Oslo, Norway : 1992). Supplement","volume":"95 452","pages":"17-21"},"PeriodicalIF":0.0,"publicationDate":"2006-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08035320600649325","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26111926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Cystinuria. 胱氨酸尿。
Pub Date : 2006-07-01 DOI: 10.1080/08035320600649473
Luca Dello Strologo, Gianfranco Rizzoni

Unlabelled: Cystinuria is an autosomal recessive disorder characterized by impaired transport of cystine, lysine, ornithine and arginine in the proximal renal tubule and in the epithelial cells of the gastrointestinal tract. Following recent progress in the genetic understanding of the disease, the traditional classification, based on the excretion of cystine and dibasic amino acids in obligate heterozygotes, may no longer be considered valid. A new classification is therefore needed: type A due to two mutations of SLC3A1 on chromosome 2, and type B due to two mutations of SLC7A9 on chromosome 19. The possibility of a third type, AB, with one mutation on each of the above-mentioned genes, is left open, but is unlikely. Clinical data show that cystinuria is more severe in males than in females in terms of stone production and early age of onset. The two types of cystinuria (A and B) have a similar outcome. A mild renal failure is present in 17% of patients. Medical treatment of this disorder is possible, but requires a composite approach: urine dilution and alkalization, and the use of drugs to form chemical bonds with the sulphydryl domains of the cystine molecule, which lower the amount of free cystine in the urine.

Conclusion: Following new achievements in the genetics of cystinuria, a new classification has been proposed. Cystinuria is more severe in males than in females, but only rarely leads to renal insufficiency. The two types of cystinuria have a similar clinical outcome. A combined medical treatment may be effective in reducing renal stone incidence.

未标记:胱氨酸尿症是一种常染色体隐性遗传病,其特征是近端肾小管和胃肠道上皮细胞中胱氨酸、赖氨酸、鸟氨酸和精氨酸的转运受损。随着对该病遗传学认识的最新进展,基于专性杂合子中胱氨酸和二碱性氨基酸排泄的传统分类可能不再被认为是有效的。因此需要一种新的分类:A型由于2号染色体上SLC3A1的两个突变,B型由于19号染色体上SLC7A9的两个突变。第三种类型,即AB型,在上述每个基因上都有一个突变的可能性仍然存在,但可能性不大。临床资料显示,胱氨酸尿症男性比女性在结石产生和早期发病方面更为严重。两种类型的胱氨酸尿(A和B)有相似的结果。17%的患者出现轻度肾功能衰竭。这种疾病的医学治疗是可能的,但需要一种综合方法:尿液稀释和碱化,以及使用药物与胱氨酸分子的巯基结构域形成化学键,从而降低尿液中游离胱氨酸的数量。结论:随着胱氨酸尿症遗传学研究的新进展,提出了一种新的分类方法。胱氨酸尿症在男性中比女性更严重,但很少导致肾功能不全。两种类型的胱氨酸尿有相似的临床结果。联合用药可有效减少肾结石的发生。
{"title":"Cystinuria.","authors":"Luca Dello Strologo,&nbsp;Gianfranco Rizzoni","doi":"10.1080/08035320600649473","DOIUrl":"https://doi.org/10.1080/08035320600649473","url":null,"abstract":"<p><strong>Unlabelled: </strong>Cystinuria is an autosomal recessive disorder characterized by impaired transport of cystine, lysine, ornithine and arginine in the proximal renal tubule and in the epithelial cells of the gastrointestinal tract. Following recent progress in the genetic understanding of the disease, the traditional classification, based on the excretion of cystine and dibasic amino acids in obligate heterozygotes, may no longer be considered valid. A new classification is therefore needed: type A due to two mutations of SLC3A1 on chromosome 2, and type B due to two mutations of SLC7A9 on chromosome 19. The possibility of a third type, AB, with one mutation on each of the above-mentioned genes, is left open, but is unlikely. Clinical data show that cystinuria is more severe in males than in females in terms of stone production and early age of onset. The two types of cystinuria (A and B) have a similar outcome. A mild renal failure is present in 17% of patients. Medical treatment of this disorder is possible, but requires a composite approach: urine dilution and alkalization, and the use of drugs to form chemical bonds with the sulphydryl domains of the cystine molecule, which lower the amount of free cystine in the urine.</p><p><strong>Conclusion: </strong>Following new achievements in the genetics of cystinuria, a new classification has been proposed. Cystinuria is more severe in males than in females, but only rarely leads to renal insufficiency. The two types of cystinuria have a similar clinical outcome. A combined medical treatment may be effective in reducing renal stone incidence.</p>","PeriodicalId":76973,"journal":{"name":"Acta paediatrica (Oslo, Norway : 1992). Supplement","volume":"95 452","pages":"31-3"},"PeriodicalIF":0.0,"publicationDate":"2006-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08035320600649473","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26111929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Macrophage activation syndrome in juvenile idiopathic arthritis. 幼年特发性关节炎的巨噬细胞激活综合征。
Pub Date : 2006-07-01 DOI: 10.1080/08035320600649713
Elisabetta Cortis, Antonella Insalaco

Unlabelled: Macrophage activation syndrome (MAS) is a rare and potentially lethal complication of chronic rheumatic diseases of childhood, in particular of systemic-onset juvenile idiopathic arthritis (s-JIA), resulting from uncontrolled activation and proliferation of T lymphocytes and macrophages. The onset, acute and dramatic, may mimic a flare of the underlying disease or a severe sepsis. Diagnosis is difficult and, until now, no specific criteria have been developed. Laboratory data show pancytopenia, coagulopathy, low ESR and low concentrations of serum albumin, and high levels of ferritin, liver enzymes and triglycerides. Activated macrophages are found in various organs, particularly in bone marrow. Most hypotheses on the mechanism underlying MAS are based on the data obtained in primary haemophagocytic lymphohistiocytosis (HLH), a genetic disease very similar to MAS. Prompt diagnosis is essential because prognosis is highly related to early treatment. The first approach was to use intravenous methylprednisolone pulse therapy; cyclosporin A was proposed in patients resistant to steroids. We describe nine patients affected by haemophagocytosis: seven patients developed MAS and two patients developed HLH. A child with s-JIA developed three episodes of MAS. After the third episode, as there was no improvement with pulses of methylprednisolone and cyclosporine, he was successfully given etanercept.

Conclusion: Our data, together with a similar, published observation, suggest that the TNF inhibitor etanercept is potentially useful for obtaining remission in children not responding to steroids and cyclosporin A.

未标记:巨噬细胞激活综合征(MAS)是儿童慢性风湿性疾病的一种罕见且潜在致命的并发症,特别是系统性发作的青少年特发性关节炎(s-JIA),由T淋巴细胞和巨噬细胞不受控制的激活和增殖引起。发作,急性和戏剧性,可能模仿潜在疾病的爆发或严重的败血症。诊断是困难的,到目前为止,还没有制定具体的标准。实验室数据显示全血细胞减少症、凝血功能障碍、低血沉和低浓度血清白蛋白、高水平铁蛋白、肝酶和甘油三酯。活化的巨噬细胞存在于各种器官中,尤其是骨髓。大多数关于MAS发病机制的假设都是基于原发性噬血细胞淋巴组织细胞增多症(HLH)的数据,这是一种与MAS非常相似的遗传病。及时诊断至关重要,因为预后与早期治疗高度相关。第一种方法是静脉注射甲基强的松龙脉冲治疗;建议对类固醇耐药患者使用环孢素A。我们描述了9例受噬血细胞症影响的患者:7例患者发展为MAS, 2例患者发展为HLH。s-JIA患儿出现三次MAS发作。第三次发作后,由于甲强的松龙和环孢素的脉冲治疗没有改善,他成功地给予依那西普。结论:我们的数据以及类似的已发表的观察结果表明,TNF抑制剂依那西普对类固醇和环孢素a无反应的儿童有潜在的缓解作用。
{"title":"Macrophage activation syndrome in juvenile idiopathic arthritis.","authors":"Elisabetta Cortis,&nbsp;Antonella Insalaco","doi":"10.1080/08035320600649713","DOIUrl":"https://doi.org/10.1080/08035320600649713","url":null,"abstract":"<p><strong>Unlabelled: </strong>Macrophage activation syndrome (MAS) is a rare and potentially lethal complication of chronic rheumatic diseases of childhood, in particular of systemic-onset juvenile idiopathic arthritis (s-JIA), resulting from uncontrolled activation and proliferation of T lymphocytes and macrophages. The onset, acute and dramatic, may mimic a flare of the underlying disease or a severe sepsis. Diagnosis is difficult and, until now, no specific criteria have been developed. Laboratory data show pancytopenia, coagulopathy, low ESR and low concentrations of serum albumin, and high levels of ferritin, liver enzymes and triglycerides. Activated macrophages are found in various organs, particularly in bone marrow. Most hypotheses on the mechanism underlying MAS are based on the data obtained in primary haemophagocytic lymphohistiocytosis (HLH), a genetic disease very similar to MAS. Prompt diagnosis is essential because prognosis is highly related to early treatment. The first approach was to use intravenous methylprednisolone pulse therapy; cyclosporin A was proposed in patients resistant to steroids. We describe nine patients affected by haemophagocytosis: seven patients developed MAS and two patients developed HLH. A child with s-JIA developed three episodes of MAS. After the third episode, as there was no improvement with pulses of methylprednisolone and cyclosporine, he was successfully given etanercept.</p><p><strong>Conclusion: </strong>Our data, together with a similar, published observation, suggest that the TNF inhibitor etanercept is potentially useful for obtaining remission in children not responding to steroids and cyclosporin A.</p>","PeriodicalId":76973,"journal":{"name":"Acta paediatrica (Oslo, Norway : 1992). Supplement","volume":"95 452","pages":"38-41"},"PeriodicalIF":0.0,"publicationDate":"2006-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08035320600649713","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26111931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Acta paediatrica (Oslo, Norway : 1992). Supplement
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1